TITLE

R&D Update -- Other Cancers

PUB. DATE
March 2003
SOURCE
PharmaWatch: Cancer;March 2003, Vol. 2 Issue 3, p11
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
Reports developments in research and development related to cancer treatment as of February 2003. Approval of the Data Safety Monitoring Board to the continuation of the thymitaq liver cancer trial of Eximias Pharmaceutical Corp.; Expansion of the renal cell carcinoma trial of Lorus Therapeutics Inc.; Potential of thalidomide therapy for multiple myeloma patients.
ACCESSION #
13830488

 

Related Articles

  • Biotech Grand Slam in the Making. Fisher, Carol L. // BioPharm International;Jun2004, Vol. 17 Issue 6, p8 

    Comments on the development of a drug for liver cancer by Eximias Pharmaceutical Corp., a biopharmaceutical company in the U.S. Information on the development of a compound called Thymitaq; Value of the drug's market potential; Assertion that if the Food & Drug Administration approves it, it...

  • Lorus to advance its anticancer drug, GTI-2501 into phase II clinical trial.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p26 

    Announces the plan of Lorus Therapeutics to advance its antisense, anticancer drug, GTI-2501 into a phase II clinical trial for the treatment of advanced metastatic prostate cancer, in the fall of 2003. Mechanism of action of GTI-2501 observed during preclinical investigations.

  • Lorus signs cancer pact with Sumitomo and Koken.  // PharmaWatch: Cancer;May 2005, Vol. 4 Issue 5, p17 

    Reports that Lorus Therapeutics Inc. has signed a collaboration agreement with Sumitomo Pharmaceuticals Co. and Koken for the development of cancer drug, Thioredoxin. Terms of the agreement; Use of Thioredoxin; Comments of the Lorus CEO, Jim Wright regarding on their collaboration with the...

  • Eximias encouraged by performance of Thymitaq in treatment of pancreatic cancer.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p38 

    Reports that Eximias Pharmaceutical Corp. has presented data suggesting that Thymitaq may be effective in disease stabilization in pancreatic cancer. Description of Thymitaq as a novel antifolate that exerts its anticancer activity through direct inhibition of thymidylate synthase.

  • FDA APPROVES LORUS/NCI GTI-2040 PHASE II CLINICAL TRIAL.  // Worldwide Biotech;Oct2003, Vol. 15 Issue 10, p1 

    Reports on the announcement of Lorus Therapeutics Inc. that the U.S. Food and Drug Administration has approved the U.S. National Cancer Institute's Investigational New Drug Application to begin a Phase II clinical trial to investigate Lorus' lead antisense drug for breast cancer, as of October 2003.

  • Anticancer Drugs. Polastro, Enrico T.; Tulcinsky, Sonia // Contract Pharma;2009, Vol. 11 Issue 8, p86 

    The article discusses the impact of anticancer drugs on the pharmaceutical industry. It notes that around 50 billion U.S. dollars is accounted for global sales of anticancer drugs which corresponds to 7% of total pharmaceutical demand and is predicted to grow 12% per annum until 2014. It cites...

  • Lorus and BioVectra sign pancreatic cancer drug deal.  // PharmaWatch: Biotechnology;January 2005, Vol. 4 Issue 1, p14 

    Reports on the commercial supply agreement between Lorus Therapeutics Inc. and BioVectra DCL company for pancreatic cancer candidate Virulizin. Completion of the technology transfer process to BioVectra; Evaluation on the use of Virulizin as a treatment of advanced pancreatic cancer in...

  • Prostate Cancer News Headlines May 15, 2003--June 14, 2003.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p26 

    Presents an update on developments concerning prostate cancer treatment, compiled as of June 14, 2003. Lorus' plan to advance its anticancer drug, GTI-2501 into phase II clinical trial; Association of the drug, Zometa, with increased bone mineral density in prostate cancer treatment;...

  • Hormonal Cancers: Key drivers in a market of change.  // PharmaWatch: Cancer;March 2003, Vol. 2 Issue 3, p19 

    Examines the market position of a number of pharmaceutical companies involved in marketing drugs for hormonal cancer. Impact of the launching of pipeline products; Approach in maintaining the companies' leadership in the market; Feasibility of anti-hormonals as a target for research and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics